Exagen Inc. Reports Impressive Q3 Results
Exagen Inc. (NASDAQ: XGN), a recognized leader in autoimmune diagnostics, has announced its remarkable financial performance for the quarter ending September 30, 2025. This quarter has proven significant for Exagen, highlighting not only financial success but also advancements in their testing solutions for autoimmune conditions.
Financial Performance Highlights
For the third quarter of 2025, Exagen reported a record revenue of $17.2 million. This represents a significant 38% increase compared to the same quarter in 2024. When accounting for prior adjustments, the revenue increased by approximately 26%, showcasing the robust demand for Exagen's innovative diagnostic solutions.
Growth in Test Volumes
Exagen has seen an impressive growth in the volume of their AVISE CTD tests, with a notable 16% increase from the previous year. This performance is reflective of the healthcare community's growing reliance on their advanced testing capabilities.
Improved Average Selling Price
The average selling price (ASP) for the AVISE CTD tests also saw an uptick, reaching $441, which is a $37 increase compared to 2024. This improvement in ASP signifies not just a price increase, but also a growing recognition of the value that Exagen's tests provide in the diagnostic process for autoimmune diseases.
Solid Cash Position
At the conclusion of Q3, Exagen's cash and cash equivalents totaled $35.7 million, increasing from $30 million in the second quarter. This robust financial position provides Exagen with the necessary resources to enhance its product development and market reach.
Product Innovations and Enhancements
During this quarter, Exagen successfully launched seronegative rheumatoid arthritis markers for anti-PAD4. This addition to the AVISE CTD panel further solidifies Exagen's commitment to expanding its testing portfolio and providing comprehensive solutions for patients with complex autoimmune conditions.
Future Projections for 2025
Looking to the future, Exagen maintains its guidance for full-year 2025 revenue to be in the range of $65 million to $70 million. The upper end of this range could potentially usher in a positive adjusted EBITDA in the fourth quarter, reflecting continued operational improvements.
Upcoming Conference Call
To further discuss the Q3 2025 financial results and strategic updates, Exagen will hold a conference call on the scheduled date, inviting stakeholders to review the company’s progress. Interested participants are encouraged to join early to ensure a smooth experience.
About Exagen
Exagen Inc. is dedicated to enhancing the diagnosis and management of autoimmune diseases through its innovative AVISE testing portfolio. The company's focus on research and development ensures that they remain at the forefront of autoimmune diagnostics. Exagen’s mission is to provide clarity in decision-making for patients suffering from chronic and debilitating autoimmune conditions.
Frequently Asked Questions
What were Exagen's revenue results for Q3 2025?
Exagen reported a record revenue of $17.2 million for Q3 2025, a 38% increase compared to the same quarter last year.
How much cash did Exagen have at the end of Q3 2025?
Exagen had $35.7 million in cash and cash equivalents at the end of Q3 2025, up from $30 million in the previous quarter.
What new products were launched by Exagen recently?
Exagen launched seronegative rheumatoid arthritis markers for anti-PAD4, enhancing their AVISE CTD panel.
What guidance has Exagen provided for 2025?
Exagen expects full-year 2025 revenue to be between $65 million and $70 million, with potential for positive adjusted EBITDA by the fourth quarter.
Where can I find more information about Exagen?
More information about Exagen Inc. and their product offerings can be found on their corporate website.
